Journal Information
Vol. 7. Issue 4.
Pages 220-223 (July - August 2011)
Share
Share
Download PDF
More article options
Vol. 7. Issue 4.
Pages 220-223 (July - August 2011)
Full text access
The influence of consumption of phytate on the bone mass in posmenopausal women of Mallorca
Influencia del consumo de fitato sobre la masa ósea en mujeres posmenopáusicas de Mallorca
Visits
5267
Ángel A. López-Gonzáleza,
Corresponding author
angarturo@gmail.com

Corresponding author.
, Félix Grasesb, Bartolomé Maríc, María Teófila Vicente-Herrerod, Antonia Costa-Bauzáb, Nieves Monroye
a Servicio de Prevención de Riesgos Laborales de GESMA, Palma de Mallorca, Balearic Islands, Spain
b Institut Universitari d’Investigació en Ciencias de la Salut (IUNICS), Universitat de les Illes Balears, Balearic Islands, Spain
c Servicio de Medicina del Deporte, Consell Insular de Mallorca, Balearic Islands, Spain
d Servicio Médico de Correos, Valencia, Spain
e Servicio de Prevención de Riesgos Laborales, Administración del Govern de les Illes Balears, Balearic Islands, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Basis

Osteoporosis is a serious health problem in the population, mainly for postmenopausal women. Therefore, it is important to develop programs to decrease prevalence. The main objective of this study is to determine the influence of phytate consumption on bone mineral density.

Patients and method

The bone mineral density was evaluated in postmenopausal women by means of dual X-ray double energy absorptiometry for calcaneous (C), lumbar spine (LS) and femoral neck (FN). The results obtained were related to the consumption of phytate by means of a dietary questionnaire.

Results

In the three different areas (C, LS, FN) we observed significantly higher values of T-score in women that consumed adequate amounts of phytate as opposed to those that did not, (C 0.1 vs −0.5, LS −1.2 and −2.5 and FN −0.2 and −1.2). There is also an increase in the T-score as more phytate is consumed, up to a maximum of two times a week (C −0.7 in non consumers, −0.2 in those that consume phytate once a week and 0.2 in those that consume phytate twice a week; LS −2.8, −1.7 and 1.1 and finally, CF −1.3, −0.6 and −0.1).

Conclusion

The results obtained seem to indicate that the adequate consumption of phytate may play an important role in the prevention of bone mineral density loss in postmenopausal women.

Keywords:
Postmenopausal osteoporosis
Phytate
Densitometry
Resumen
Fundamento

La osteoporosis supone un gran problema de salud para la población, especialmente para el colectivo de mujeres posmenopáusicas, siendo por ello importante que se establezcan políticas preventivas que hagan disminuir su prevalencia. El objetivo de este estudio es valorar la influencia que tiene el consumo de fitato en los niveles de densidad mineral ósea.

Población y método

Se calcula la masa ósea en mujeres posmenopáusicas empleando DEXA de calcáneo (C), columna lumbar (CL) y cuello de fémur (CF) y se relacionan estos valores con el consumo de fitato determinado mediante encuesta alimentaria.

Resultados

En las tres localizaciones se observan mayores valores de T-score en las mujeres que consumen fitato en cantidades adecuadas frente a las que no lo consumen (C: 0,1 frente a −0,5; CL: −1,2 y −2,5, y CF: −0,2 y −1,2). También aumenta el T-score a medida que lo hace la cantidad de fitato consumida, hasta un máximo de 2 veces a la semana (C: −0,7 en no consumidores, −0,2 en consumidores de fitato de una vez por semana y 0,2 en los que consumen 2 veces por semana; CL −2,8, −1,7 y −1,1, respectivamente, y finalmente CF: −1,3, −0,6 y −0,1, respectivamente).

Conclusiones

Los resultados obtenidos parecen indicar que el consumo regular de fitato puede tener un papel importante en la prevención del déficit de masa ósea en mujeres posmenopáusicas.

Palabras clave:
Osteoporosis posmenopáusica
Fitato
Densitometría
Full text is only aviable in PDF
References
[1.]
NIH Consensus Development Panel.
Osteoporosis Prevention. Diagnosis, and Therapy.
JAMA, 285 (2000), pp. 785-795
[2.]
J.A. Eisman.
Genetics of osteoporosis.
Endocr Rev, 20 (1999), pp. 788-804
[3.]
J. Paulino.
Osteoporosis: importancia, epidemiología y manifestaciones clínicas.
Medicine, 8 (2000), pp. 15-22
[4.]
M. Díaz-Curiel, J.J. García, J.L. Carrasco, J. Honorato, R. Pérez-Cano, A. Rapado, et al.
Prevalencia de osteoporosis determinada por densitometría en la población femenina española.
Med Clin (Barc), 116 (2001), pp. 86-88
[5.]
L.J. Melton.
How many women have osteoporosis now?.
J Bone Miner Res, 10 (1995), pp. 175-177
[6.]
P. Persi.
Densitometría ósea 2000.
Med Clin (Barc), 114 (2000), pp. 540-542
[7.]
E. Mellanby.
Rickets-producing and anticalcifying action of phytate.
J Physiol, 109 (1949), pp. 488-533
[8.]
F. Grases, B.M. Simonet, J. Perelló, A. Costa-Bauzá, R.M. Prieto.
Effect of Phytate on element bioavailability in the second generation rats.
J Trace Elem Med Biol, 17 (2004), pp. 229-234
[9.]
F. Grases, A. Llobera.
Determination of phytic acid in urine by ICP atomic emission spectrometry.
Analytical Letters, 29 (1996), pp. 1193-1199
[10.]
F. Grases, B.M. Simonet, R.M. Prieto, J.G. March.
Dietary phytate and mineral bioavailability.
J Trace Elem Med Biol, 15 (2001), pp. 221-228
[11.]
F. Grases, B.M. Simonet, I. Vucenik, R.M. Prieto, A. Costa-Bauzá, J.G. March, et al.
Absorption and excretion of orally administered inositol hexaphosphate IP6 or phytate in humans.
BioFactors, 15 (2001), pp. 53-61
[12.]
F. Grases, A. Costa-Bauzá.
Phytate is a powerful agent for preventing calcifications in biologicals fluids: usefulness in renal lithiasis treatment.
Anticancer Res, 19 (1999), pp. 3717-3722
[13.]
F. Grases, A. Costa-Bauzá, E. Königsberger, L.C. Königsberger.
Kinetic versus thermodynamic factors in calcium renal lithiasis.
Int Urol Nephrol, 32 (2000), pp. 19-27
[14.]
F. Grases, B.M. Simonet, J.G. March, R.M. Prieto.
Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion.
BJU Int, 85 (2000), pp. 138-142
[15.]
F. Grases, J.G. March, R.M. Prieto, B.M. Simonet, A. Costa-Bauzá, A. García-Raja, et al.
Urinary phytate in calcium oxalate stone formers and healthy people. Dietary effects on phytate excretion.
Scand J Urol Nephrol, 34 (2000), pp. 162-164
[16.]
F. Grases, P. Sanchos, J. Perello, B. Isern, R.M. Prieto, C. Fernández-Palomeque, et al.
Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats.
Frontiers in Bioscience, 11 (2006), pp. 136-142
[17.]
López-González AA. Influencia de diferentes factores de riesgo incluyendo el myoinositol hexafosfato cálcico-magnésico en los niveles de densidad mineral ósea en trabajadores de Mallorca. Tesis Doctoral; 2007.
[18.]
Grases F, Sanchis P, Costa-Bauzá A, Perelló J. Phytate (Myo-inositol hexakisphosphate) inhibits hydroxyapatite dissolution [Under preparation].
[19.]
López-González AA, Grases F, Roca P, Marí B, Vicente-Herrero MT, Costa-Bauzá A. Phytate (Myo-inositol hexaphosphate) and risk factors for osteoporosis [in press]. J Med Food. 2008;11:747–52.
[20.]
Grases F, Sanchis P, Perelló J, Prieto RM, López-González AA. Effect of phytate (Myo-inositol hexaphosphate) on bone characteristics in ovariectomized rats. J Med Food. 2010 [in press].
[21.]
H. Fleisch.
Development of bisphosphonates.
Breast Cancer Res, 4 (2002), pp. 30-34
[22.]
H. Fleisch.
Bisphosphonates in osteoporosis.
Eur Spine J, 12 (2003), pp. 142-146
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Download PDF
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?